Anti-LCAT Antibody (4M692) is a Rabbit antibody targeting LCAT. Anti-LCAT Antibody (4M692) can be used in WB,IHC-P,IHC-Fr,ICC/IF,IF,IP.

IgG

4M692

Human,Mouse,Rat

1. 25 μg total protein per lane of various lysates (see on figure) probed with LCAT monoclonal antibody, unconjugated (TMAB-08241) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r. T. for 60 min.
2. Paraformaldehyde-fixed, paraffin embedded Human Liver; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with LCAT Monoclonal Antibody, Unconjugated (TMAB-08241) at 1: 200 overnight at 4°C, followed by conjugation to the Goat Anti-Rabbit IgG H&L Secondary Antibody-HRP and DAB staining.

WB: 1:500-2000; IHC-P: 1:100-500; IHC-Fr: 1:100-500; ICC/IF: 1:50-200; IF: 1:100-500; IP: 1:20-50

Monoclonal

A synthesized peptide: human LCAT

Human

LCAT

Phosphatidylcholine-sterol acyltransferase

Central enzyme in the extracellular metabolism of plasma lipoproteins. Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs). The cholesterol ester is then transported back to the liver. Has a preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines. Also produced in the brain by primary astrocytes, and esterifies free cholesterol on nascent APOE-containing lipoproteins secreted from glia and influences cerebral spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and the cholesterol transporter ABCA1, plays a key role in the maturation of glial-derived, nascent lipoproteins. Required for remodeling high-density lipoprotein particles into their spherical forms.